The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma

Current Topics in Microbiology and Immunology

Volumn 351, Issue 1, 2012, Pages 181-220

  Oosterhoff, D ^a   Sluijter, B J R ^a   Hangalapura, B N ^a   De Gruijl, T D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ALPHA INTERFERON; CD103 ANTIGEN; CD14 ANTIGEN; CD40 ANTIGEN; CP 870893; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMIQUIMOD; INTERLEUKIN 18; INTERLEUKIN 2; LANGERIN; MDX 1106; MELANOMA ANTIGEN 3; MELANOMA VACCINE; PROGRAMMED DEATH 1 ANTIBODY; PROTEIN ANTIBODY; RESIQUIMOD; T6 ANTIGEN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL SUBPOPULATION; CUTANEOUS MELANOMA; DENDRITIC CELL; DERMAL DENDRITIC CELL; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; EFFECTOR CELL; EXPLANT; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPOTENTIATION; LANGERHANS CELL; LOW DRUG DOSE; MACROPHAGE; MELANOMA; METASTASIS; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIMARY TUMOR; PRIORITY JOURNAL; SENTINEL LYMPH NODE; SKIN CANCER; SKIN CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

ANTIGENS, CD; CANCER VACCINES; CELL LINEAGE; CYTOKINES; DERMIS; HUMANS; IMMUNITY; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; LANGERHANS CELLS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 80053545768     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82_2011_136     Document Type: Article

References (223)

1. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N (2008) Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181:776-784
2. Anon (2010) http://clinicaltrials.gov/ct2/show/NCT00960752
3. Altin JG, Parish CR (2006) Liposomal vaccines-targeting the delivery of antigen. Methods 40:39-52 (Pubitemid 44415497)
4. Angel CE, Lala A, Chen CJ, Edgar SG, Ostrovsky LL, Dunbar PR (2007) CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts. Int Immunol 19:1271-1279 (Pubitemid 47604728)
5. Ascierto PA, Kirkwood JM (2008) Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 6:62
6. Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, Vicari A, Trinchieri G (2005) Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med 201:1157-1167 (Pubitemid 40528442)
7. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T lymphocyte antigen-4. J Clin Oncol 23:6043-6053
8. Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW, Henn V, Kloetzel PM, Gurka S, Kroczek RA (2010) Superior antigen cross-presentation and XCR1 expression define human CD11c+ CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 207:1273-1281
9. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648 (Pubitemid 32786276)
10. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Jr., Morton DL, Ross MI, Sober AJ, Sondak VK (2009a) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206
11. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009b) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206
12. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YT, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811 (Pubitemid 30365397)
13. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451-6458 (Pubitemid 32783251)
14. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687 (Pubitemid 43237609)
15. Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I, Allan RS, Wojtasiak M, Shortman K, Carbone FR, Brooks AG, Heath WR (2009) Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol 10:488-495
16. Bong AB, Bonnekoh B, Franke I, Schon MP, Ulrich J, Gollnick H (2002) Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 205:135-138
17. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196:1627-1638 (Pubitemid 36026474)
18. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM (2004) In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199: 815-824 (Pubitemid 38375201)
19. Bostick PJ, Morton DL, Turner RR, Huynh KT, Wang HJ, Elashoff R, Essner R, Hoon DS (1999) Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 17:3238-3244 (Pubitemid 29470658)
20. Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Sales F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM (2009) Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 101:869-877
21. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175
22. Brand CU, Hunger RE, Yawalkar N, Gerber HA, Schaffner T, Braathen LR (1999) Characterization of human skin-derived CD1a-positive lymph cells. Arch Dermatol Res 291:65-72 (Pubitemid 29116519)
23. Brandao JG, Scheper RJ, Lougheed SM, Curiel DT, Tillman BW, Gerritsen WR, van den Eertwegh AJ, Pinedo HM, Haisma HJ, de Gruijl TD (2003) CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 21:2268-2272 (Pubitemid 36561319)
24. Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Yeo CJ, Emmons RV, Witkiewicz AK (2009) Expression of indoleamine 2, 3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 8: 1930-1934
25. Cecchi R, Buralli L, Innocenti S, De Gaudio C (2007) Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol 34:512-515 (Pubitemid 47228525)
26. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL (2006) Characterization of CD4+ CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169-1177 (Pubitemid 46638815)
27. Chang BA, Cross JL, Najar HM, Dutz JP (2009) Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine 27:5791-5799
28. Chaperot L, Blum A, Manches O, Lui G, Angel J, Molens JP, Plumas J (2006) Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 176:248-255 (Pubitemid 43023269)
29. Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222:357-368 (Pubitemid 351430366)
30. Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4:336-347 (Pubitemid 38649276)
31. Chung EY, Liu J, Homma Y, Zhang Y, Brendolan A, Saggese M, Han J, Silverstein R, Selleri L, Ma X (2007) Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity 27:952-964 (Pubitemid 350251222)
32. Clark RA (2010) Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol 130:362-370
33. Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE (2010) Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines 9:519-525
34. Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R (2006) Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6:659-670 (Pubitemid 44298215)
35. Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen DR (2001) Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 14:604-608 (Pubitemid 32554086)
36. Combadiere B, Mahe B (2008) Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microbiol Infect Dis 31:293-315 (Pubitemid 351315120)
37. Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, Vu Manh TP, Baranek T, Storset AK, Marvel J, Boudinot P, Hosmalin A, Schwartz-Cornil I, Dalod M (2010) The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med 207:1283-1292
38. De Gruijl TD, Luykx-de Bakker SA, Tillman BW, van den Eertwegh AJ, Buter J, Lougheed SM, van der Bij GJ, Safer AM, Haisma HJ, Curiel DT, Scheper RJ, Pinedo HM, Gerritsen WR (2002) Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol 169:5322-5331 (Pubitemid 35217206)
39. De Gruijl TD, Pinedo HM, Scheper RJ (2004) Immunotherapy of cancer through dendritic cell-targeted gene transfer. In: Curiel DT, Douglass JT (eds) Cancer gene therapy. Humana Press, Totowa, pp 143-172
40. De Gruijl TD, Sombroek CC, Lougheed SM, Oosterhoff D, Buter J, van den Eertwegh AJ, Scheper RJ, Pinedo HM (2006) A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. J Immunol 176:7232-7242 (Pubitemid 43849023)
41. Dranoff G (2003) GM-CSF-secreting melanoma vaccines. Oncogene 22:3188-3192 (Pubitemid 36713771)
42. Dranoff G (2009) Targets of protective tumor immunity. Ann NY Acad Sci 1174:74-80
43. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, Gunther G, Johnston I, Lanzavecchia A, Nagasaka T, Okada T, Vermi W, Winkels G, Yamamoto T, Zysk M, Yamaguchi Y, Schmitz J (2001) BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 194:1823-1834 (Pubitemid 34028661)
44. Edele F, Molenaar R, Gutle D, Dudda JC, Jakob T, Homey B, Mebius R, Hornef M, Martin SF (2008) Cutting edge: instructive role of peripheral tissue cells in the imprinting of T cell homing receptor patterns. J Immunol 181:3745-3749
45. Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611-618 (Pubitemid 34752469)
46. Eggermont AM (2009) Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 15:6745-6747
47. Engering A, van Vliet SJ, Hebeda K, Jackson DG, Prevo R, Singh SK, Geijtenbeek TB, van Krieken H, van Kooyk Y (2004) Dynamic populations of dendritic cell-specific ICAM-3 grabbing nonintegrin-positive immature dendritic cells and liver/lymph node-specific ICAM-3 grabbing nonintegrin-positive endothelial cells in the outer zones of the paracortex of human lymph nodes. Am J Pathol 164:1587-1595 (Pubitemid 38529761)
48. Enk AH, Jonuleit H, Saloga J, Knop J (1997) Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73:309-316 (Pubitemid 27508890)
49. Enk AH, Katz SI (1992) Identification and induction of keratinocyte-derived IL-10. J Immunol 149:92-95
50. Essner R, Kojima M (2002) Dendritic cell function in sentinel nodes. Oncology (Williston Park) 16:27-31
51. Fanning SL, George TC, Feng D, Feldman SB, Megjugorac NJ, Izaguirre AG, Fitzgerald-Bocarsly P (2006) Receptor cross-linking on human plasmacytoid dendritic cells leads to the regulation of IFN-alpha production. J Immunol 177:5829-5839 (Pubitemid 44628796)
52. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL (2009) Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res 15:7029-7035
53. Farrand KJ, Dickgreber N, Stoitzner P, Ronchese F, Petersen TR, Hermans IF (2009) Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens. J Immunol 183:7732-7742
54. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25:2546-2553 (Pubitemid 47041228)
55. Flacher V, Tripp CH, Stoitzner P, Haid B, Ebner S, Del Frari B, Koch F, Park CG, Steinman RM, Idoyaga J, Romani N (2010) Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis. J Invest Dermatol 130:755-762
56. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM (2009) PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 182:5240-5249
57. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-1034
58. Geissmann F, Dieu-Nosjean MC, Dezutter C, Valladeau J, Kayal S, Leborgne M, Brousse N, Saeland S, Davoust J (2002) Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med 196:417-430
59. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K (2010) Development of monocytes, macrophages, and dendritic cells. Science 327:656-661
60. Gerlini G, Di Gennaro P, Mariotti G, Urso C, Chiarugi A, Pimpinelli N, Borgognoni L (2010) Indoleamine 2, 3-dioxygenase+ cells correspond to the BDCA2+ plasmacytoid dendritic cells in human melanoma sentinel nodes. J Invest Dermatol 130:898-901
61. Gerlini G, Mariotti G, Chiarugi A, Di Gennaro P, Caporale R, Parenti A, Cavone L, Tun-Kyi A, Prignano F, Saccardi R, Borgognoni L, Pimpinelli N (2008) Induction of CD83+ CD14+ nondendritic antigen-presenting cells by exposure of monocytes to IFN-alpha. J Immunol 181:2999-3008
62. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO (2004) Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 165:1853-1863 (Pubitemid 39578365)
63. Gerlini G, Urso C, Mariotti G, Di Gennaro P, Palli D, Brandani P, Salvadori A, Pimpinelli N, Reali UM, Borgognoni L (2007) Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol 125:184-193 (Pubitemid 47562900)
64. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI (1999) Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17:976-983 (Pubitemid 29109331)
65. Ghebeh H, Mohammed S, Al Omair A, Qattan A, Lehe C, Al Qudaihi G, Elkum N, Alshabanah M, Bin AS, Tulbah A, Ajarim D, Al Tweigeri T, Dermime S (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8:190-198 (Pubitemid 43671234)
66. Ginhoux F, Collin MP, Bogunovic M, Abel M, Leboeuf M, Helft J, Ochando J, Kissenpfennig A, Malissen B, Grisotto M, Snoeck H, Randolph G, Merad M (2007) Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state. J Exp Med 204:3133-3146
67. Glaspy J, Ribas A, Chmielowski B (2009) Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? J Clin Oncol 27:2896-2897
68. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718 (Pubitemid 43247141)
69. Granelli-Piperno A, Pritsker A, Pack M, Shimeliovich I, Arrighi JF, Park CG, Trumpfheller C, Piguet V, Moran TM, Steinman RM (2005) Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J Immunol 175:4265-4273 (Pubitemid 41361960)
70. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD (2007) Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 156:337-345 (Pubitemid 46095963)
71. Green DS, Dalgleish AG, Belonwu N, Fischer MD, Bodman-Smith MD (2008) Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol 159:606-614
72. Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patino JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN (2004) CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 22:1700-1708 (Pubitemid 38447218)
73. Gursel M, Verthelyi D, Klinman DM (2002) CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol 32:2617-2622
74. Haenssle H, Buhl T, Knudsen S, Krueger U, Rosenberger A, Reich K, Neumann C (2008) CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin-10-induced regression to macrophage-like monocytes. Exp Dermatol 17:177-187 (Pubitemid 351233862)
75. Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM (2008) CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res 14:5626-5634
76. Hangalapura BN, Oosterhoff D, Aggarwal S, Wijnands PGJTB, van de Ven R, Santegoets SJAM, van den Tol MP, Hooijberg E, Pereboev A, van den Eertwegh AJM, Curiel DT, Scheper RJ, De Gruijl TD (2010) Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus. J Immunother 33:706-715
77. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, Giese T, Gires O, Endres S, Hartmann G (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63:6478-6487 (Pubitemid 37255200)
78. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194:769-779 (Pubitemid 32983013)
79. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R, Zinda M (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16:487-497
80. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712-4717 (Pubitemid 36457795)
81. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
82. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U (2008) Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 31:520-527
83. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531-4537 (Pubitemid 34441357)
84. Huang D, Pereboev AV, Korokhov N, He R, Larocque L, Gravel C, Jaentschke B, Tocchi M, Casley WL, Lemieux M, Curiel DT, Chen W, Li X (2008) Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. Gene Ther 15:298-308 (Pubitemid 351223466)
85. Huang RR, Wen DR, Guo J, Giuliano AE, Nguyen M, Offodile R, Stern S, Turner R, Cochran AJ (2000) Selective modulation of paracortical dendritic cells and T-lymphocytes in breast cancer sentinel lymph nodes. Breast J 6:225-232 (Pubitemid 30622094)
86. Hunter TB, Alsarraj M, Gladue RP, Bedian V, Antonia SJ (2007) An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol 65:479-486 (Pubitemid 46632548)
87. Ichikawa HT, Williams LP, Segal BM (2002) Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J Immunol 169: 2781-2787 (Pubitemid 34921028)
88. Ishigami S, Ueno S, Matsumoto M, Okumura H, Arigami T, Uchikado Y, Setoyama T, Arima H, Sasaki K, Kitazono M, Shinchi H, Kijima Y, Natsugoe S (2010) Prognostic value of CD208-positive cell infiltration in gastric cancer. Cancer Immunol Immunother 59:389-395
89. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293-12297
90. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, Gon G, Toyoda M, Tanigawa N (2003) Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 104:92-97 (Pubitemid 36184151)
91. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC (1998) Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161:3042-3049 (Pubitemid 28425730)
92. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A (2001) Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31:3388-3393 (Pubitemid 33100532)
93. Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G (2007) MFG-E8-mediated uptake of apoptotic cells by APCs links the pro-and anti-inflammatory activities of GM-CSF. J Clin Invest 117:1902-1913 (Pubitemid 47036324)
94. Johnson TS, Mahnke K, Storn V, Schonfeld K, Ring S, Nettelbeck DM, Haisma HJ, Le Gall F, Kontermann RE, Enk AH (2008) Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clin Cancer Res 14:8169-8177
95. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, Vulink AJ, Hart DN, Radford KJ (2010) Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 207:1247-1260
96. Jonuleit H, Schmitt E, Steinbrink K, Enk AH (2001) Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 22:394-400 (Pubitemid 32673646)
97. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW (2001) Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 61: 206-214 (Pubitemid 32095719)
98. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704 (Pubitemid 351600389)
99. Kim YS, Kim YJ, Lee JM, Han SH, Ko HJ, Park HJ, Pereboev A, Nguyen HH, Kang CY (2010) CD40-targeted recombinant adenovirus significantly enhances the efficacy of DC and B cell-based anti-tumor vaccines. Hum Gene Ther 21:1697-1706
100. Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ, Bulanhagui CA (2010) Phase II trial of tremelimumab (CP-675, 206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 16: 1042-1048
101. Klechevsky E, Liu M, Morita R, Banchereau R, Thompson-Snipes L, Palucka AK, Ueno H, Banchereau J (2009) Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum Immunol 70:281-288
102. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, Briere F, Chaussabel D, Zurawski G, Palucka AK, Reiter Y, Banchereau J, Ueno H (2008) Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29: 497-510
103. Korokhov N, Noureddini SC, Curiel DT, Santegoets SJ, Scheper RJ, de Gruijl TD (2005) A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. Mol Pharm 2:218-223 (Pubitemid 40917418)
104. Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, Liu Y, Salcedo R, Yu H (2009a) Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res 69:2497-2505
105. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, Deng J, Soifer HS, Raubitschek A, Forman S, Rossi JJ, Pardoll DM, Jove R, Yu H (2009b) In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 27:925-932
106. Koschella M, Voehringer D, Pircher H (2004) CD40 ligation in vivo induces bystander proliferation of memory phenotype CD8 T cells. J Immunol 172:4804-4811 (Pubitemid 38456402)
107. Krieg AM (2001) Now I know my CpGs. Trends Microbiol 9:249-252 (Pubitemid 32522795)
108. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760 (Pubitemid 34293438)
109. Krieg AM (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27:161-167
110. Lacelle MG, Jensen SM, Fox BA (2009) Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res 15:6881-6890
111. Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, Gaudi I, Timar J (2007) Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 56:1459-1469 (Pubitemid 47024707)
112. Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitemaker JH, Kapsenberg ML, de Jong EC (2007) Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 127:331-341 (Pubitemid 46106911)
113. Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, Morton DL, Essner R (2005) Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 11:107-112 (Pubitemid 40075784)
114. Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, Mazzella F, Antonia SJ, Mellor AL, Munn DH (2003) Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 83:1457-1466 (Pubitemid 37267829)
115. Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K (2009) Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 15:1623-1634
116. Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P (2008) Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 118:1165-1175 (Pubitemid 351364623)
117. Macagno A, Napolitani G, Lanzavecchia A, Sallusto F (2007) Duration, combination and timing: the signal integration model of dendritic cell activation. Trends Immunol 28:227-233 (Pubitemid 46654873)
118. Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH (2005) Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 65: 7007-7012 (Pubitemid 41060741)
119. Mancuso G, Gambuzza M, Midiri A, Biondo C, Papasergi S, Akira S, Teti G, Beninati C (2009) Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 10:587-594
120. Mathers AR, Janelsins BM, Rubin JP, Tkacheva OA, Shufesky WJ, Watkins SC, Morelli AE, Larregina AT (2009) Differential capability of human cutaneous dendritic cell subsets to initiate Th17 responses. J Immunol 182:921-933
121. Mathers AR, Larregina AT (2006) Professional antigen-presenting cells of the skin. Immunol Res 36:127-136 (Pubitemid 46398588)
122. Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R (2002) Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 188:177-182 (Pubitemid 35398875)
123. Mellor AL, Munn DH (2008) Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 8:74-80
124. Merad M, Ginhoux F, Collin M (2008) Origin, homeostasis and function of
125. Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ, Adema GJ (2008) Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood 111:4245-4253
126. Mikszta JA, Laurent PE (2008) Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook. Expert Rev Vaccines 7:1329-1339
127. Mitsui H, Okamoto T, Kanzaki M, Inozume T, Shibagaki N, Shimada S (2010) Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity. Br J Dermatol 162:29-41
128. Mohty M, Olive D, Gaugler B (2004) Plasmacytoid DCs and cancer: a new role for an enigmatic cell. Trends Immunol 25:397-398
129. Molenkamp BG, Sluijter BJR, van Leuwen PAM, Santegoets SJAM, Meijer S, Wijnands PGJT, Haanen JBAG, van den Eertwegh AJM, Scheper RJ, de Gruijl TD (2008) Local administration of PF-3512676 CpG-B instigates tumor-specific CD8(+) T-cell reactivity in melanoma patients. Clin Cancer Res 14:4532-4542
130. Molenkamp BG, van Leeuwen PAM, Meijer S, Sluijter BJR, Wijnands PGJT, Baars A, van den Eertwegh AJM, Scheper RJ, de Grujil TD (2007) Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 13:2961-2969 (Pubitemid 46849571)
131. Molenkamp BG, van Leeuwen PAM, van den Eertwegh AJM, Sluijter BJR, Scheper RJ, Meijer S, de Gruijl TD (2006) Immunomodulation of the melanoma sentinel lymph node: A novel adjuvant therapeutic option. Immunobiology 211:651-661
132. Molenkamp BG, Vuylsteke RJCL, van Leeuwen PAM, Meijer S, Vos W, Wijnands PGJT, Scheper RJ, de Gruijl TD (2005) Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am J Pathol 167:1301-1307 (Pubitemid 41541416)
133. Mora JR, Cheng G, Picarella D, Briskin M, Buchanan N, von Andrian UH (2005) Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin-and gut-associated lymphoid tissues. J Exp Med 201:303-316 (Pubitemid 40189439)
134. Morelli AE, Rubin JP, Erdos G, Tkacheva OA, Mathers AR, Zahorchak AF, Thomson AW, Falo LD Jr, Larregina AT (2005) CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells. J Immunol 175:7905-7915 (Pubitemid 41798351)
135. Morton DL, Cochran AJ, Thompson JF (2008) The rationale for sentinel-node biopsy in primary melanoma. Nat Clin Pract Oncol 5:510-511
136. Mouries J, Moron G, Schlecht G, Escriou N, Dadaglio G, Leclerc C (2008) Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 112:3713-3722
137. Munn DH, Mellor AL (2006) The tumor-draining lymph node as an immune-privileged site. Immunol Rev 213:146-158 (Pubitemid 44401499)
138. Munn DH, Mellor AL (2007) Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:1147-1154
139. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL (2004a) Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114:280-290 (Pubitemid 39071633)
140. Munn DH, Sharma MD, Mellor AL (2004b) Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2, 3-dioxygenase activity in dendritic cells. J Immunol 172:4100-4110 (Pubitemid 38375222)
141. Nagaraj S, Collazo M, Corzo CA, Youn JI, Ortiz M, Quiceno D, Gabrilovich DI (2009) Regulatory myeloid suppressor cells in health and disease. Cancer Res 69:7503-7506
142. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ (2009) Skin immune sentinels in health and disease. Nat Rev Immunol 9:679-691
143. Nestle FO, Nickoloff BJ (2007) Deepening our understanding of immune sentinels in the skin. J Clin Invest 117:2382-2385 (Pubitemid 47494337)
144. Nickoloff BJ, Fivenson DP, Kunkel SL, Strieter RM, Turka LA (1994) Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. Clin Immunol Immunopathol 73:63-68 (Pubitemid 24310780)
145. Ochoa MT, Loncaric A, Krutzik SR, Becker TC, Modlin RL (2008) "Dermal dendritic cells" comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages. J Invest Dermatol 128:2225-2231
146. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M, Nakajima Y (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11:2947-2953 (Pubitemid 40525197)
147. Ouwehand K, Santegoets SJ, Bruynzeel DP, Scheper RJ, de Gruijl TD, Gibbs S (2008) CXCL12 is essential for migration of activated Langerhans cells from epidermis to dermis. Eur J Immunol 38:3050-3059
148. Ouwehand K, Scheper RJ, de Gruijl TD, Gibbs S (2010) Epidermis-to-dermis migration of immature Langerhans cells upon topical irritant exposure is dependent on CCL2 and CCL5. Eur J Immunol 40:2026-2034
149. Palm NW, Medzhitov R (2009) Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227:221-233
150. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J (2003) Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 170:3488-3494 (Pubitemid 36359214)
151. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S (1998) Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58:2489-2499 (Pubitemid 28275413)
152. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372-8377 (Pubitemid 36842552)
153. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E, Le Moine A, Faure F, Donckier V, Sancho D, Cerundolo V, Bonnet D, Reis e Sousa (2010) Characterization of human DNGR-1 BDCA3 leukocytes as putative equivalents of mouse CD8alpha dendritic cells. J Exp Med 207:1261-1271
154. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296 (Pubitemid 46697910)
155. Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, Volk HD (1995) Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med 181:1887-1892
156. Ray CM, Kluk M, Grin CM, Grant-Kels JM (2005) Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol 44:428-434 (Pubitemid 40691992)
157. Reddy ST, Swartz MA, Hubbell JA (2006) Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 27:573-579 (Pubitemid 44708833)
158. Riboldi E, Daniele R, Cassatella MA, Sozzani S, Bosisio D (2009) Engagement of BDCA-2 blocks TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. Immunobiology 214:868-876
159. Ridolfi L, Ridolfi R, Ascari-Raccagni A, Fabbri M, Casadei S, Gatti A, Trevisan G, Righini MG (2001) Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J Eur Acad Dermatol Venereol 15:218-223 (Pubitemid 32903899)
160. Rieger R, Kipps TJ (2003) CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B cell lymphoma vaccines. Cancer Res 63:4128-4135 (Pubitemid 36917937)
161. Rivas JM, Ullrich SE (1992) Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol 149:3865-3871 (Pubitemid 23068866)
162. Robbins SH, Walzer T, Dembele D, Thibault C, Defays A, Bessou G, Xu H, Vivier E, Sellars M, Pierre P, Sharp FR, Chan S, Kastner P, Dalod M (2008) Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol 9:R17
163. Romani N, Clausen BE, Stoitzner P (2010) Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev 234:120-141
164. Romero P, Cerottini JC, Speiser DE (2006) The human T cell response to melanoma antigens. Adv Immunol 92:187-224 (Pubitemid 44834534)
165. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. Journal of Experimental Medicine 188:1641-1650 (Pubitemid 28516109)
166. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233-240
167. Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL, Shepherd D, Colonna M, Cerundolo V (2003) Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 33:1052-1062 (Pubitemid 36546693)
168. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, Carlyle JR, (2008) Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 118:2098-2110 (Pubitemid 351872329)
169. Santegoets SJ, Bontkes HJ, Stam AG, Bhoelan F, Ruizendaal JJ, van den Eertwegh AJ, Hooijberg E, Scheper RJ, de Gruijl TD (2008) Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model. J Immunol 180:4540-4549
170. Santegoets SJ, Gibbs S, Kroeze K, Van de Van R, Scheper RJ, Borrebaeck CA, de Gruijl TD, Lindstedt M (2008b) Transcriptional profiling of human skin-resident Langerhans cells and CD1a+ dermal dendritic cells: differential activation states suggest distinct functions. J Leukoc Biol 84:143-151 (Pubitemid 351960289)
171. Sarnaik AA, Weber JS (2009) Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 15:169-173
172. Schmidt C (2007) News: clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 25:825-826 (Pubitemid 47236890)
173. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483
174. Schon MP, Schon M (2008) TLR7 and TLR8 as targets in cancer therapy. Oncogene 27:190-199
175. Sen D, Forrest L, Kepler TB, Parker I, Cahalan MD (2010) Selective and site-specific mobilization of dermal dendritic cells and Langerhans cells by Th1-and Th2-polarizing adjuvants. Proc Natl Acad Sci USA 107:8334-8339
176. Serra P, Amrani A, Yamanouchi J, Han B, Thiessen S, Utsugi T, Verdaguer J, Santamaria P (2003) CD40 ligation releases immature dendritic cells from the control of regulatory CD4+ CD25+ T cells. Immunity 19:877-889 (Pubitemid 37542307)
177. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase. J Clin Invest 117:2570-2582 (Pubitemid 47494358)
178. Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH (2009) Indoleamine 2, 3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113:6102-6111
179. Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K (2008) Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother 57: 1263-1270
180. Skrzeczynska-Moncznik J, Wawro K, Stefanska A, Oleszycka E, Kulig P, Zabel BA, Sulkowski M, Kapinska-Mrowiecka M, Czubak-Macugowska M, Butcher EC, Cichy J (2009) Potential role of chemerin in recruitment of plasmacytoid dendritic cells to diseased skin. Biochem Biophys Res Commun 380:323-327
181. Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA (2009) Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15: 7036-7044
182. Smalley KS (2010) PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs 11:699-706
183. Sparber F, Tripp CH, Hermann M, Romani N, Stoitzner P (2010) Langerhans cells and dermal dendritic cells capture protein antigens in the skin: possible targets for vaccination through the skin. Immunobiology 215:770-779
184. Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27:571-577 (Pubitemid 35463873)
185. Starz H, Balda BR (2007) Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: a follow-up study of 148 patients. Int J Cancer 121:689-693 (Pubitemid 46986505)
186. Statius Muller MG, Borgstein PJ, Pijpers R, van Leeuwen PA, van Diest PJ, Gupta A, Meijer S (2000) Reliability of the sentinel node procedure in melanoma patients: analysis of failures after long-term follow-up. Ann Surg Oncol 7:461-468 (Pubitemid 30439306)
187. Stoitzner P, Green LK, Jung JY, Price KM, Tripp CH, Malissen B, Kissenpfennig A, Hermans IF, Ronchese F (2008) Tumor immunotherapy by epicutaneous immunization requires langerhans cells. J Immunol 180:1991-1998
188. Stoitzner P, Sparber F, Tripp CH (2010a) Langerhans cells as targets for immunotherapy against skin cancer. Immunol Cell Biol 88:431-437
189. Stoitzner P, Stingl G, Merad M, Romani N (2010b) Langerhans cells at the interface of medicine, science, and industry. J Invest Dermatol 130:331-335
190. Sun X, Hodge LM, Jones HP, Tabor L, Simecka JW (2002) Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine 20:1466-1474 (Pubitemid 34131690)
191. Tacken PJ, de Vries IJ, Torensma R, Figdor CG (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7:790-802 (Pubitemid 47480309)
192. Teunissen MBM, Koomen CW, Jansen J, de Waal MR, Schmitt E, Van den Wijngaard RM, Das PK, Bos JD (1997) In contrast to their murine counterparts, normal human keratinocytes and human epidermoid cell lines A431 and HaCaT fail to express IL-10 mRNA and protein. Clin Exp Immunol 107:213-223 (Pubitemid 27019832)
193. Teunissen MBM, Haniffa M, Collin M (2011) Insight into the immunobiology of human skin and cutaneous dendritic cell subsets to perfection intradermal vaccination design. Curr Top Microbiol Immunol (in press)
194. Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, Timares L, Korokhov N, O'Neill AM, de Gruijl TD, Glasgow JN, Tani K, Curiel DT (2009) A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 27:7116-7124
195. Tillman BW, de Gruijl TD, Luykx-de Bakker SA, Scheper RJ, Pinedo HM, Curiel TJ, Gerritsen WR, Curiel DT (1999) Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 162:6378-6383 (Pubitemid 29309357)
196. Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT (2000) Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papilloma-virus 16-induced tumor cells in a murine model. Cancer Res 60:5456-5463
197. Timares L, Douglas JT, Tillman BW, Krasnykh V, Curiel DT (2004) Adenovirus-mediated gene delivery to dendritic cells. Methods Mol Biol 246:139-154
198. Toka FN, Gierynska M, Suvas S, Schoenberger SP, Rouse BT (2005) Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. Virology 331:151-158 (Pubitemid 39593641)
199. Toriyama K, Wen DR, Paul E, Cochran AJ (1993) Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant-melanoma of the skin. J Investig Dermatol 100:S269-S273
200. Tuve S, Chen BM, Liu Y, Cheng TL, Toure P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, Li ZY, Roffler SR, Lieber A (2007) Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 67:5929-5939 (Pubitemid 46985029)
201. Van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG (2004) Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 64:4357-4365 (Pubitemid 38802444)
202. Van Der Aar AMG, Sylva-Steenland RMR, Bos JD, Kapsenberg ML, de Jong EC, Teunissen MBM (2007) Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol 178:1986-1990 (Pubitemid 46233394)
203. Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S, Berenzi A, Cella M, Colonna M (2003) Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 200:255-268 (Pubitemid 36748035)
204. Villadangos JA, Young L (2008) Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 29:352-361
205. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ (2007) Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876-883 (Pubitemid 350002889)
206. Vuylsteke RJ, van Leeuwen PA, Meijer S, Wijnands PG, Statius Muller MG, Busch DH, Scheper RJ, de Gruijl TD (2002) Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol 161:19-26 (Pubitemid 34760766)
207. Vuylsteke RJCL, Molenkamp BG, Gietema HA, van Leeuwen PAM, Wijnands PGJT, Vos W, van Diest PJ, Scheper RJ, Meijer S, de Gruijl TD (2004) Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Research 64:8456-8460 (Pubitemid 39491787)
208. Vuylsteke RJCL, Molenkamp BG, van Leeuwen PAM, Meijer S, Wijnands PGJT, Haanen JBAG, Scheper RJ, de Gruijl TD (2006) Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clin Cancer Res 12:2826-2833
209. Waller EK (2007) The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist 12 (Suppl 2):22-26
210. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, Kirkwood JM (2007) Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 13:1523-1531 (Pubitemid 46450444)
211. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J (2009) PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol 21:1065-1077
212. Warren TL, Bhatia SK, Acosta AM, Dahle CE, Ratliff TL, Krieg AM, Weiner GJ (2000) APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol 165:6244-6251
213. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988
214. Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y (2009) Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin Cancer Res 15:4612-4621
215. Wenzel J, Tormo D, Tuting T (2008) Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospects. Handb Exp Pharmacol 183:201-220
216. Wolf IH, Cerroni L, Kodama K, Kerl H (2005) Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 141:510-514 (Pubitemid 40547412)
217. Wolf IH, Kodama K, Cerroni L, Kerl H (2007) Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol 29: 237-241 (Pubitemid 46801921)
218. Yoneyama H, Matsuno K, Zhang Y, Nishiwaki T, Kitabatake M, Ueha S, Narumi S, Morikawa S, Ezaki T, Lu B, Gerard C, Ishikawa S, Matsushima K (2004) Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol 16:915-928 (Pubitemid 38967174)
219. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798-809
220. Zaba LC, Fuentes-Duculan J, Steinman RM, Krueger JG, LowesMA(2007) Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest 117:2517-2525 (Pubitemid 47494353)
221. Zaba LC, Krueger JG, Lowes MA (2009) Resident and " inflammatory" dendritic cells in human skin. J Invest Dermatol 129:302-308
222. Zang X, Allison JP (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 13:5271-5279 (Pubitemid 47510350)
223. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T, Curiel DT, Galanaud P, Capron F, Emilie D, Curiel TJ (2001) Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7:1339-1346 (Pubitemid 34007939)